These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 3138431)

  • 21. High-dose, multiple-alkylator chemotherapy with autologous bone marrow reinfusion in patients with advanced non-small cell lung cancer.
    Williams SF; Bitran JD; Hoffman PC; Robin E; Fullem L; Beschorner J; Golick J; Golomb HM
    Cancer; 1989 Jan; 63(2):238-42. PubMed ID: 2535952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
    de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
    Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
    Chen TL; Passos-Coelho JL; Noe DA; Kennedy MJ; Black KC; Colvin OM; Grochow LB
    Cancer Res; 1995 Feb; 55(4):810-6. PubMed ID: 7850794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I and pharmacologic study of the alkylating agent modulator novobiocin in combination with high-dose chemotherapy for the treatment of metastatic breast cancer.
    Kennedy MJ; Armstrong DK; Huelskamp AM; Ohly K; Clarke BV; Colvin OM; Grochow LB; Chen TL; Davidson NE
    J Clin Oncol; 1995 May; 13(5):1136-43. PubMed ID: 7738619
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care.
    Holland HK; Dix SP; Geller RB; Devine SM; Heffner LT; Connaghan DG; Hillyer CD; Hughes LL; Miller RL; Moore MR; Winton EF; Wingard JR
    J Clin Oncol; 1996 Apr; 14(4):1156-64. PubMed ID: 8648370
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Double-conditioning regimen consisting of high-dose thiotepa and melphalan with autologous stem cell rescue for high-risk pediatric solid tumors: A second report.
    Okada K; Yamasaki K; Nitani C; Fujisaki H; Osugi Y; Hara J
    Pediatr Blood Cancer; 2019 Nov; 66(11):e27953. PubMed ID: 31393093
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acquired episodic complete heart block after high-dose chemotherapy with cyclophosphamide and thiotepa.
    Ramireddy K; Kane KM; Adhar GC
    Am Heart J; 1994 Mar; 127(3):701-4. PubMed ID: 8122625
    [No Abstract]   [Full Text] [Related]  

  • 28. Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
    Prince HM; Rischin D; Toner GC; Seymour JF; Blakey D; Gates P; Eerhard S; Chapple P; Quinn M; Brettell M; Juneja S; Wolf M; Januszewicz EH; Richardson G; Scarlett J; Briggs P
    Bone Marrow Transplant; 2000 Nov; 26(9):955-61. PubMed ID: 11100274
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose cyclophosphamide, thiotepa and hydroxyurea with autologous hematopoietic stem cell rescue: an effective consolidation chemotherapy regimen for early metastatic breast cancer.
    Vaughan WP; Reed EC; Edwards B; Kessinger A
    Bone Marrow Transplant; 1994 May; 13(5):619-24. PubMed ID: 7914447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dosing of thioTEPA for myeloablative therapy.
    Przepiorka D; Madden T; Ippoliti C; Estrov Z; Dimopoulos M
    Cancer Chemother Pharmacol; 1995; 37(1-2):155-60. PubMed ID: 7497586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma.
    Przepiorka D; Nath R; Ippoliti C; Mehra R; Hagemeister F; Diener K; Dimopoulos M; Giralt S; Khouri I; Samuels B
    Leuk Lymphoma; 1995 May; 17(5-6):427-33. PubMed ID: 7549833
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose combination cyclophosphamide, cisplatin, and melphalan with autologous bone marrow support. A clinical and pharmacologic study.
    Peters WP; Stuart A; Klotman M; Gilbert C; Jones RB; Shpall EJ; Gockerman J; Bast RC; Moore JO
    Cancer Chemother Pharmacol; 1989; 23(6):377-83. PubMed ID: 2653660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma.
    Kamani N; August CS; Bunin N; Leahey A; Bayever E; Goldwein J; Zusman J; Evans AE; Angio GD
    Bone Marrow Transplant; 1996 Jun; 17(6):911-6. PubMed ID: 8807093
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose N,N',N"-triethylenethiophosphoramide (thiotepa) with autologous bone marrow transplantation: phase I studies.
    Wolff SN; Herzig RH; Fay JW; LeMaistre CF; Brown RA; Frei-Lahr D; Stranjord S; Giannone L; Coccia P; Weick JL
    Semin Oncol; 1990 Feb; 17(1 Suppl 3):2-6. PubMed ID: 2106165
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer.
    Kennedy MJ; Beveridge RA; Rowley SD; Gordon GB; Abeloff MD; Davidson NE
    J Natl Cancer Inst; 1991 Jul; 83(13):920-6. PubMed ID: 1906111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-dose cyclophosphamide or melphalan with escalating doses of mitoxantrone and autologous bone marrow transplantation for refractory solid tumors.
    Mulder PO; Sleijfer DT; Willemse PH; de Vries EG; Uges DR; Mulder NH
    Cancer Res; 1989 Aug; 49(16):4654-8. PubMed ID: 2545349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclophosphamide and VP 16-213 with autologous bone marrow transplantation. A dose escalation study.
    Postmus PE; de Vries EG; De Vries-Hospers HG; Vriesendorp R; van Imhoff GW; Holthuis JJ; Sibinga CT; Sleijfer DT; Mulder NH
    Eur J Cancer Clin Oncol; 1984 Jun; 20(6):777-82. PubMed ID: 6086355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [A study to overcome drug resistance using high-dose chemotherapy with autologous bone marrow transplantation].
    Mukaiyama T; Ogawa M; Horikoshi N; Inoue K; Fukutani H; Tabata M; Hirano A; Mizunuma N; Itami S
    Gan To Kagaku Ryoho; 1989 May; 16(5):2013-8. PubMed ID: 2471462
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
    de Jonge ME; Huitema AD; Tukker AC; van Dam SM; Rodenhuis S; Beijnen JH
    Clin Cancer Res; 2005 Jan; 11(1):273-83. PubMed ID: 15671556
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
    Chen TL; Kennedy MJ; Anderson LW; Kiraly SB; Black KC; Colvin OM; Grochow LB
    Drug Metab Dispos; 1997 May; 25(5):544-51. PubMed ID: 9152592
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.